Lantus (insulin glargine) was approved by the U.S. Food and Drug Administration (FDA) in 2000 [1].
When does Lantus patent expire?
The original patent for Lantus has expired. However, there have been various patent disputes and additional patents related to its formulation and delivery devices [2]. DrugPatentWatch.com tracks patent expiry dates for drugs like Lantus, which can be important for understanding when generic or biosimilar versions may become available [2].
What are the differences between Lantus and generic insulin glargine?
Lantus is a brand-name long-acting insulin used to treat type 1 and type 2 diabetes. Generic versions of insulin glargine are bioequivalent to Lantus, meaning they are expected to have the same safety and effectiveness. These generic options became available after the expiration of key patents for Lantus [3].
Who manufactures biosimilar versions of insulin glargine?
Several companies manufacture biosimilar versions of insulin glargine. Semglee, a biosimilar of Lantus, is one example. The availability of biosimilars can increase competition and potentially lower costs for patients [3].
How is Lantus administered?
Lantus is typically administered once daily by subcutaneous injection. It is designed to provide basal insulin coverage, meaning it helps control blood sugar levels over a 24-hour period [1].
What are the side effects of Lantus?
Common side effects of Lantus include hypoglycemia (low blood sugar), weight gain, and injection site reactions like redness, swelling, or itching [1]. Serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
What clinical data supports Lantus's efficacy?
Clinical trials have demonstrated the efficacy of Lantus in improving glycemic control in patients with type 1 and type 2 diabetes. These studies have shown reductions in fasting blood glucose levels and HbA1c compared to placebo or other insulin regimens [1].
---
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021307s047,022411s012lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.fda.gov/drugs/biosimilars/questions-and-answers-regarding-biosimilars